| Industry | 卫生和社会工作业 | ||||||||||||||||||||||||
| Company Introduction | 公司眼科医疗专注于大、中型城市，优先布局“北上广深”超一线城市，辐射一线重点城市。目前，公司已开设了14家中心眼科专科医院，并围绕中心医院，通过视光诊所群，实现对区域市场的精耕细作，让居民能够便捷地享受到高品质眼科医疗服务。近年来，公司不断提升重点布局区域内医疗网络的广度、深度以及密度，在上海等核心城市，深化一城多院布局。2022年，新建上海崇明院区（上海光正新视界瞳亮眼科医院有限公司）、明悦诊所（上海新视界明悦眼科门诊部有限公司）；2023年，新建明澈诊所（上海新视界明澈眼科诊所有限公司）；目前，公司在上海地区布局有4家医院3家诊所，其中，中山医院有20年品牌沉淀，严肃医疗、消费医疗各个病种建设完善，是公司的学术中心、品牌沉淀中心；中兴医院位于上海火车站北广场，立足上海，辐射长三角，覆盖江苏、浙江，是公司的疑难眼病会诊中心，同时，自2018年以来，中兴医院坚定病种转型思路，大力发展屈视光等消费眼科，逐步形成了一支以廉井财院长为核心、兼具学术和网络影响的专家队伍，屈光收入占比超过白内障；东区医院位于浦东陆家嘴，定位打造品质医疗中心，通过环境、装修、设备、专家、服务规范性等多个层面体现医疗品质。崇明医院是公司在上海建设的第四家医院，位于崇明CBD繁华地段，主要面对“一老一小”，主攻白内障与视光病种。四家医院差异化定位，各有多长、互相补充，在上海乃至长三角地区实现了明显的区域优势。公司在眼科一城多院模式建设、专科医院打造、运营管理方面，逐步沉淀出了一套标准化、体系化的管控与管理模式，逐步形成了以“长三角”、“京津冀”、“珠三角”、“胶东半岛”、“成渝”五大核心城市群为中心平台的连锁诊疗体系，连锁优势进一步显现。 | ||||||||||||||||||||||||
| Main Business | 眼科医院的投资、管理业务，能源与钢结构业务。 | ||||||||||||||||||||||||
| Legal Representative | 周永麟 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 李薇 | ||||||||||||||||||||||||
| Solicitors | 新疆天阳律师事务所 | ||||||||||||||||||||||||
| Auditors | 立信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0991-3766551 | ||||||||||||||||||||||||
| Fax No | 0991-3766551 | ||||||||||||||||||||||||
| Website | www.gzykcn.com | ||||||||||||||||||||||||
| guangzheng@gzss.cc;liwei@xsjyk.com；shanjingjing@xsjyk.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 17/12/2010 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.020 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 0.547 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 1.976B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |